Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Rifampicin reduces plasma concentrations of celiprolol.

European journal of clinical pharmacology - 1 Jan 2004

Lilja J J, Niemi M, Neuvonen P J

Abstract excerpt

OBJECTIVE: The beta-adrenoceptor-blocking agent celiprolol undergoes negligible metabolism, but is a substrate for P-glycoprotein. Our objective was to investigate the effects of rifampicin on the pharmacokinetics of celiprolol in healthy subjects. METHODS: In a randomized cross-over study with two phases and a washout of 4 weeks, ten healthy volunteers received a 5-day pretreatment with rifampicin (600 mg daily)...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adrenergic beta-Antagonists
Share to Antibiotics, Antitubercular
Share to Area Under Curve

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to ATP Binding Cassette Transporter, Subfamily B, Member 1

Share to Cross-Over Studies

Share to Half-Life

Share to Polymorphism, Genetic

Share to Rifampin

Source

Identifiers

PMID: 14614579
DOI: 10.1007/s00228-003-0694-z

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Rifampicin reduces plasma concentrations of celiprolol.PMID 14614579Read ↗

CYP2D6 genotype and induction of intestinal drug transporters by rifampin predict presystemic clearance of carvedilol in healthy subjects.Semantic proximity Read ↗

Unexpected lack of effect of the rifampin-induced P-glycoprotein on the oral bioavailability of its substrate, talinolol, in humans: implication in phenotyping.Semantic proximity Read ↗

Disposition and sterol-lowering effect of ezetimibe are influenced by single-dose coadministration of rifampin, an inhibitor of multidrug transport proteins.Semantic proximity Read ↗

Factors associated with variability in rifampin plasma pharmacokinetics and the relationship between rifampin concentrations and induction of efavirenz clearance.Semantic proximity Read ↗

Rifampicin markedly decreases the exposure to oral and intravenous tramadol.Semantic proximity Read ↗

Roles of rifampicin in drug-drug interactions: underlying molecular mechanisms involving the nuclear pregnane X receptorSemantic proximity Read ↗

Rifampicin alters atorvastatin plasma concentration on the basis of SLCO1B1 521T>C polymorphism.Semantic proximity Read ↗

Human intestinal P‐glycoprotein activity estimated by the model substrate digoxinSemantic proximity Read ↗

Rifampicin population pharmacokinetics and pharmacogenomic evaluation of SLCO1B1 gene in tuberculosis patients.Semantic proximity Read ↗

Lymphocyte P-glycoprotein expression and activity before and after rifampicin in man.Semantic proximity Read ↗

Unexpected Effect of Rifampin on the Pharmacokinetics of Linezolid: In Silico and In Vitro Approaches to Explain Its MechanismSemantic proximity Read ↗

Induction of intestinal P-glycoprotein by St John's wort reduces the oral bioavailability of talinolol.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.